Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ticagrelor is an oral, reversible, direct-acting inhibitor of the adenosine diphosphate receptor P2Y12 that has a more rapid onset and more pronounced platelet inhibition than clopidogrel. METHODS: In this multicenter, double-blind, randomized trial, we compared ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and clopidogrel (300-to-600-mg loading dose, 75 mg daily thereafter) for the prevention of cardiovascular events in 18,624 patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation. RESULTS: At 12 months, the primary end point--a composite of death from vascular causes, myocardial infarction, or stroke--had occurred in 9.8% of patients receiving ticagrelor as compared with 11.7% of those receiving clopidogrel (hazard ratio, 0.84; 95% confidence interval [CI], 0.77 to 0.92; P<0.001). Predefined hierarchical testing of secondary end points showed significant differences in the rates of other composite end points, as well as myocardial infarction alone (5.8% in the ticagrelor group vs. 6.9% in the clopidogrel group, P=0.005) and death from vascular causes (4.0% vs. 5.1%, P=0.001) but not stroke alone (1.5% vs. 1.3%, P=0.22). The rate of death from any cause was also reduced with ticagrelor (4.5%, vs. 5.9% with clopidogrel; P<0.001). No significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% and 11.2%, respectively; P=0.43), but ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting (4.5% vs. 3.8%, P=0.03), including more instances of fatal intracranial bleeding and fewer of fatal bleeding of other types. CONCLUSIONS: In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding. (ClinicalTrials.gov number, NCT00391872.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [311]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [503]
In the citing paper
“International trials of various pharmacotherapies have sometimes found discordant results in patients enrolled in the United States than seen in overall trial results.19–32”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
In the citing paper
“The reasons range from low numbers of patients enrolled in the United States to potential differences in background medical management or in patient risk profiles.”
From REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States (2020) · cites this paper as [19]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Writing Committee Members, Antman, E. M., Anbe, D. T., Armstrong, P. W., Bates, E. R., Green, L. A., Hand, M., Hochman, J. S., Krumholz, H. M., Kushner, F. G., et al. (2004) · Circulation · doi:10.1161/01.cir.0000134791.68010.fa · Cited by 8,356
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationBraunwald, E., Antman, E. M., Beasley, J. W., Califf, R. M., Cheitlin, M. D., Hochman, J. S., Jones, R. H., Kereiakes, D., Kupersmith, J., Levin, T. N., et al. (2000) · Circulation · doi:10.1161/01.cir.102.10.1193 · Cited by 4,487
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Mehta, S. R., Yusuf, S., Peters, R. J., Bertrand, M. E., Lewis, B. S., Natarajan, M. K., Malmberg, K., Rupprecht, H.-J., Zhao, F., Chrolavicius, S., et al. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05701-4 · Cited by 2,809
急性心筋梗塞の疑いのある17187症例におけるストレプトキナーゼ静脈内投与,アスピリン経口投与,上記2つの併用または無処置の無作偽試験 ISIS-2
Dienstl, F., Backer, G. D., Cairns, J., Pedersen, F., Kala, R., Boissel, J., Schroeder, R., Horgan, J., & Tognoni, G. (1988) · The Lancet · Cited by 2,754
Mehta, S. R., Yusuf, S., & Peters, R. J. G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00559-7 · Cited by 2,578
Research works printed but not linked: 2
- 10.1016/S0140-6736(01)05701-4 · DOI · Paper page
- 1988, Lancet, 2, 349
Cited by
Items 701–800 of 1,005
Management of Patients With NSTE-ACS
Rodríguez, F., & Mahaffey, K. W. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.599 · Cited by 80
Self-citationGupta, R., Moore, J. M., Griessenauer, C. J., Adeeb, N., Patel, A. S., Youn, R., Poliskey, K., Thomas, A. J., & Ogilvy, C. S. (2016) · World Neurosurgery · doi:10.1016/j.wneu.2016.09.013 · Cited by 68
Pharmacokinetics and Pharmacodynamics of Approved and Investigational P2Y12 Receptor Antagonists
Schilling, U., Dingemanse, J., & Ufer, M. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00864-4 · Cited by 72
Regional anaesthesia in patients on antithrombotic drugs: Joint ESAIC/ESRA guidelines
Kietaibl, S., Ferrandis, R., Godier, A., Llau, J., Lobo, C., Macfarlane, A. J., Schlimp, C. J., Vandermeulen, E., Volk, T., von Heymann, C., et al. (2022) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000001600 · Cited by 289
Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention
Åkerblom, A., James, S. K., Koutouzis, M., Lagerqvist, B., Stenestrand, U., Svennblad, B., & Oldgren, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.093 · Cited by 70
Self-citationHigh platelet reactivity and clinical outcome – Fact and fiction
Sibbing, D., Byrne, R. A., Bernlochner, I., & Kastrati, A. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-01-0040 · Cited by 72
Bioactive Extracellular Matrix Scaffold Promotes Adaptive Cardiac Remodeling and Repair
Mewhort, H. E. M., Svystonyuk, D. A., Turnbull, J. D., Teng, G., Belke, D. D., Guzzardi, D. G., Park, D. S., Kang, S., Hollenberg, M. D., & Fedak, P. W. M. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.05.005 · Cited by 67
“Approximately 5% to 10% of patients admitted with an acute coronary syndrome receive coronary artery bypass graft surgery early after injury (37).”
BackgroundFinancial burden, distress, and toxicity in cardiovascular disease
Slavin, S. D., Khera, R., Zafar, S. Y., Nasir, K., & Warraich, H. J. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.04.011 · Cited by 71
Cuculi, F., Lim, C. C. S., & BANNING, A. P. (2010) · Heart · doi:10.1136/hrt.2009.186189 · Cited by 70
Antiplatelet drugs: which targets for which treatments?
Gachet, C. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12947 · Cited by 77
Pre-treatment with P2Y 12 inhibitors in ACS patients: who, when, why, and which agent?
Sibbing, D., Kastrati, A., & Berger, P. B. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv717 · Cited by 76
Xi, Z., Fang, F., Wang, J., AlHelal, J., Zhou, Y., & Liu, W. (2017) · Platelets · doi:10.1080/09537104.2017.1413178 · Cited by 67
“The PLATO trial found that treatment with ticagrelor significant reduced the rate of death from vascular cause in patients with ACS compared with clopidogrel [45].”
MethodGille, A., D’Andrea, D. M., Tortorici, M. A., Härtel, G., & Wright, S. D. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.310538 · Cited by 72
“For example, data from the Plato trial show that approximately half of the new major adverse cardiovascular events in the year after AMI occur in the first month.(1) At least half of these events occur in nonculprit arteries,(2) presumably through the rupture or erosion of the diffuse plaque that characterizes coronar…”
MethodLeone, A. M., Scalone, G., Maria, G. L. D., Tagliaferro, F., Gardi, A., Clemente, F., Basile, E., Cialdella, P., Caterina, A. R. D., Porto, I., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m07_02 · Cited by 68
Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors During Elective Coronary Revascularization
Winchester, D. E., Wen, X., Brearley, W. D., Park, K. E., Anderson, R. D., & Bavry, A. A. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.030 · Cited by 66
Atherosclerosis: from biology to pharmacological treatment
Riccioni, G., & Sblendorio, V. T. (2012) · 老年心脏病学杂志:英文版 · doi:10.3724/sp.j.1263.2012.02132 · Cited by 82
D’Souza, M., Sarkisian, L., Saaby, L., Poulsen, T. S., Gerke, O., Larsen, T. B., Diederichsen, A. C. P., Jangaard, N., Diederichsen, S. Z., Hosbond, S. E., et al. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.044 · Cited by 70
von Elverfeldt, D., Maier, A., Duerschmied, D., Braig, M., Witsch, T., Wang, X., Mauler, M., Neudorfer, I., Menza, M., Idzko, M., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.008157 · Cited by 65
P2Y 6 Deficiency Limits Vascular Inflammation and Atherosclerosis in Mice
Stachon, P., Peikert, A., Michel, N. A., Hergeth, S., Marchini, T., Wolf, D., Dufner, B., Hoppe, N., Ayata, C. K., Grimm, M., et al. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303585 · Cited by 77
Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors
Siller-Matula, J. M., Trenk, D., Krähenbühl, S., Michelson, A. D., & Delle‐Karth, G. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12445 · Cited by 67
Stent Thrombosis: Incidence, Predictors and New Technologies
Buchanan, G. L., Basavarajaiah, S., & Chieffo, A. (2012) · Thrombosis · doi:10.1155/2012/956962 · Cited by 69
Gaztañaga, J., Farkouh, M. E., Rudd, J. H. F., Brotz, T. M., Rosenbaum, D. H., Mani, V., Kerwin, T. C., Taub, R. A., Tardif, J., Tawakol, A. A., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.02.027 · Cited by 68
Gagne, J. J., Bykov, K., Choudhry, N. K., Toomey, T., Connolly, J. G., & Avorn, J. (2013) · BMJ · doi:10.1136/bmj.f5307 · Cited by 67
Alexopoulos, D., Moulias, A., Koutsogiannis, N., Xanthopoulou, I., Kakkavas, A., Mavronasiou, E., Davlouros, P., & Hahalis, G. (2013) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.113.000293 · Cited by 66
Andell, P., James, S. K., Cannon, C. P., Cyr, D. D., Himmelmänn, A., Husted, S., Keltai, M., Koul, S. M., Santoso, A., Steg, P. G., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002490 · Cited by 71
Self-citationSafety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention
Velders, M. A., Abtan, J., Angiolillo, D. J., Ardissino, D., Harrington, R. A., Hellkamp, A. S., Himmelmänn, A., Husted, S., Katus, H. A., Meier, B., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-308963 · Cited by 70
Self-citationAntiplatelet therapy – a summary for the general physicians
Thachil, J. V. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-2-152 · Cited by 83
Moore, J. M., Adeeb, N., Shallwani, H., Gupta, R., Patel, A. S., Griessenauer, C. J., Youn, R., Siddiqui, A. H., Ogilvy, C. S., & Thomas, A. J. (2017) · Neurosurgery · doi:10.1093/neuros/nyx079 · Cited by 66
Role of genetic testing in patients undergoing percutaneous coronary intervention
Moon, J. Y., Franchi, F., Rollini, F., Rios, J. R. R., Kureti, M., Cavallari, L. H., & Angiolillo, D. J. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1353909 · Cited by 69
“leading cause of drug discontinuation [34,36].”
Olier, I., Sirker, A., Hildick‐Smith, D., Kinnaird, T. D., Ludman, P., de Belder, M., Baumbach, A., Byrne, J., Rashid, M. O., Curzen, N. P., et al. (2018) · Heart · doi:10.1136/heartjnl-2017-312366 · Cited by 66
Kwok, C. S., Rao, S. V., Potts, J. E., Kontopantelis, E., Rashid, M. O., Kinnaird, T. D., Curzen, N. P., Nolan, J., Bagur, R., & Mamas, M. A. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.01.248 · Cited by 67
Bosch, X., Marrugat, J., & Sanchis, J. M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002130.pub4 · Cited by 69
Cardiovascular Disease in Women
Stock, E. O., & Redberg, R. (2012) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2012.07.001 · Cited by 65
Hsu, S., Ton, V., Ashen, M. D., Martin, S. S., Gluckman, T. J., Kohli, P., Sisson, S. D., Blumenthal, R. S., & Blaha, M. J. (2013) · Clinical Cardiology · doi:10.1002/clc.22137 · Cited by 69
A review of current treatments strategies based on paromomycin for leishmaniasis
Matos, A. P. D. S., Viçosa, A. L., Ré, M. I., Ricci‐Júnior, E., & Holandino, C. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.101664 · Cited by 69
De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes
Shoji, S., Kuno, T., Fujisaki, T., Takagi, H., Briasoulis, Α., Deharo, P., Cuisset, T., Latib, A., & Kohsaka, S. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.012 · Cited by 68
Kwon, O., & Park, D. (2022) · JACC Asia · doi:10.1016/j.jacasi.2021.12.005 · Cited by 71
“Along with the key findings in the large-scaled PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis In Myocardial Infarction 54) trial that a 60-mg dose of ticagrelor might offer a more attractive risk-ben…”
BackgroundInfluentialAntithrombotic treatment strategies in patients with established coronary atherosclerotic disease
Valgimigli, M., Aboyans, V., Angiolillo, D. J., Atar, D., Capodanno, D., Halvorsen, S., James, S. K., Jüni, P., Kunadian, V., Landi, A., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad032 · Cited by 67
Self-citationDiagnosis and Management of Ischemic Heart Disease
Franchini, M., Cervellin, G., & Lippi, G. (2013) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1333543 · Cited by 70
Teng, R., Mitchell, P., & Butler, K. A. (2012) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-012-1369-4 · Cited by 69
Prevention of stent thrombosis: challenges and solutions
Lotfi, A. S., & Reejhsinghani, R. S. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s43357 · Cited by 71
International differences in treatment effect: do they really exist and why?†
Pocock, S., Calvo, G., Marrugat, J., Prasad, K., Tavazzi, L., Wallentin, L. C., Zannad, F. M., & Garcia, A. A. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht071 · Cited by 66
Self-citationSánchez-Ramos, J. G., Dávila-Fajardo, C. L., Frías, P. T., Díaz-Villamarín, X., Martínez-González, L. J., Huertas, S. M., Gómez, F. B., Borrego, J. C., Pavés, A. B., Guzmán, M. C. M., et al. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.09.088 · Cited by 65
Handelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
Würtz, M., & Grove, E. L. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803251925 · Cited by 71
Na, Y., Byeon, J., Wang, M., Huh, H. W., Son, G.-H., Sunghoon, J. E. O. N., Bang, K.-H., Kim, S., Lee, H.-J., Lee, H.-K., et al. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s190426 · Cited by 67
“TCG was approved for use in patients with acute coronary syndrome based on a phase III study (Platelet Inhibition and Patient Outcomes), which showed a significant benefit compared with clopidogrel.(5,6) However, TCG exhibits very low solubility (,10 μg/mL) at all pH values.”
MethodYun, J. E., Kim, Y. J., Park, J. J., Kim, S., Park, K., Cho, M. S., Nam, G., & Park, D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012078 · Cited by 71
“The key findings of our study conflicted with those of the pivotal RCTs of ticagrelor and prasugrel.(2,3) In our study, compared with clopidogrel, ticagrelor use significantly increased the rate of bleeding events without reducing major cardiovascular events.”
ResultLuca, G. D., Navarese, E. P., Cassetti, E., Verdoia, M., & Suryapranata, H. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.08.063 · Cited by 64
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes
Wiviott, S. D., & Steg, P. G. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60213-6 · Cited by 76
Self-citationEsper, S. A., Subramaniam, K., & Tanaka, K. A. (2014) · Seminars in Cardiothoracic and Vascular Anesthesia · doi:10.1177/1089253214532375 · Cited by 68
Hanel, R. A., Taussky, P., Dixon, T., Miller, D. A., Sapin, M., Nordeen, J. D., Tawk, R. G., Navarro, R., Johns, G. S., & Freeman, W. D. (2013) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2013-010699 · Cited by 64
Larmore, C. J., Effron, M. B., Molife, C., DeKoven, M., Zhu, Y. E., Lu, J., Karkare, S. U., Lieu, H. D., Lee, W. C., & Vetrovec, G. W. (2015) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.26279 · Cited by 69
Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Stable Coronary Artery Disease
Husted, S., Storey, R. F., Bliden, K. P., Tantry, U. S., Høimark, L., Butler, K. A., Wei, C., Teng, R., & Gurbel, P. A. (2012) · Clinical Pharmacokinetics · doi:10.2165/11599830-000000000-00000 · Cited by 67
Self-citationGremmel, T., Yanachkov, I. B., Yanachkova, M. I., Wright, G. E., Wider, J. M., Undyala, V. V. R., Michelson, A. D., Frelinger, A. L., & Przyklenk, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306885 · Cited by 67
Ducrocq, G., Schulte, P. J., Becker, R. C., Cannon, C. P., Harrington, R. A., Held, C., Himmelmänn, A., Lassila, R., Storey, R. F., Sorbets, E., et al. (2015) · EuroIntervention · doi:10.4244/eijy14m09_11 · Cited by 64
Self-citationClopidogrel is safer than ticagrelor in regard to bleeds: A closer look at the PLATO trial
DiNicolantonio, J. J., D’Ascenzo, F., Tomek, A., Chatterjee, S., Niazi, A. K., & Biondi‐Zoccai, G. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.06.135 · Cited by 64
Management of acute coronary syndromes in older adults
Morici, N., Servi, S. D., Luca, L. D., Crimi, G., Montalto, C., Rosa, R. D., Luca, G. D., Rubboli, A., Valgimigli, M., & Savonitto, S. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab391 · Cited by 69
Daneault, B., Généreux, P., Kirtane, A. J., Witzenbichler, B., Guagliumi, G., Paradis, J., Fahy, M. P., Mehran, R., & Stone, G. W. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.08.040 · Cited by 65
Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature
Rogers, K. C., Oliphant, C. S., & Finks, S. W. (2015) · Drugs · doi:10.1007/s40265-015-0364-3 · Cited by 70
Aspirin Resistance: Current Status and Role of Tailored Therapy
Grinstein, J., & Cannon, C. P. (2012) · Clinical Cardiology · doi:10.1002/clc.22031 · Cited by 70
Self-citationKubica, A., Obońska, K., Fabiszak, T., & Kubica, J. (2016) · Current Medical Research and Opinion · doi:10.1080/03007995.2016.1182901 · Cited by 69
Ticagrelor – toward more efficient platelet inhibition and beyond
Kubisa, M. J., Jeżewski, M. P., Gąsecka, A., Siller-Matula, J. M., & Postula, M. A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s152369 · Cited by 72
“The superiority of ticagrelor over clopidogrel has been initially established based on the results of the multicenter, double-blind, randomized PLATO (Platelet Inhibition and Patient Outcomes) study, which compared ticagrelor and clopidogrel for the prevention of cardiovascular (CV) events in 18,624 patients with ACS,…”
Kang, J., Han, J., Ahn, Y., Chae, S. C., Kim, Y. J., Chae, I., Hur, S., Seong, I. W., Chae, J.-K., Cho, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1626697 · Cited by 65
Clopidogrel withdrawal: Is there a “rebound” phenomenon?
Sambu, N., Warner, T. D., & Curzen, N. P. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-08-0554 · Cited by 68
Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity
Chau, K. H.-Y., Kirtane, A. J., Easterwood, R. M., Redfors, B., Zhang, Z., Witzenbichler, B., Weisz, G., Stuckey, T., Brodie, B. R., Rinaldi, M. J., et al. (2021) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2020.12.005 · Cited by 65
Poor response to clopidogrel: current and future options for its management
Campo, G. C., Fileti, L., Valgimigli, M., Tebaldi, M., Cangiano, E., Cavazza, C., Marchesini, J., & Ferrari, R. (2010) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-010-0457-5 · Cited by 62
Lemesle, G., Schurtz, G., Bauters, C., & Hamon, M. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12907 · Cited by 61
Johnston, A., Jones, W. S., & Hernandez, A. F. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0749-2 · Cited by 64
Abtan, J., Bhatt, D. L., Elbez, Y., Sorbets, E., Eagle, K. A., Ikeda, Y., Wu, D., Hanson, M. E., Hannachi, H., Singhal, P. K., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22583 · Cited by 66
Self-citationTicagrelor Removal From Human Blood
Angheloiu, G. O., Gugiu, G. B., Ruse, C. I., Pandey, R., Dasari, R. R., & Whatling, C. A. (2017) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2017.01.007 · Cited by 62
Généreux, P., Giustino, G., Redfors, B., Palmerini, T., Witzenbichler, B., Weisz, G., Stuckey, T., Maehara, A., Mehran, R., Kirtane, A. J., et al. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.103 · Cited by 65
Zheng, Y., Wu, T., Yang, Y., Hou, X., Gao, Y., Chen, Y., Yang, Y., Li, X., Ma, X., Ma, Y., et al. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz059 · Cited by 63
Gąsecka, A., Nieuwland, R., Budnik, M., Dignat‐George, F., Eyileten, C., Harrison, P., Lacroix, R., Leroyer, A. S., Opolski, G., Pluta, K., et al. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14689 · Cited by 66
“15 However, improved prognosis on ti-cagrelor cannot be explained solely by ticagrelor anti-aggregatory effect, because the anti-aggregatory effect is achieved directly after ticagrelor administration, whereas reduction in mortality starts after at least 2 weeks and increases with the length of…”
BackgroundSundaram, V., Bloom, C. I., Zakeri, R., Halcox, J., Cohen, A. T., Bowrin, K., Brière, J., Banerjee, A., Simon, D. I., Cleland, J. G. F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz880 · Cited by 65
Gragnano, F., Heg, D., Franzone, A., McFadden, E. P., Leonardi, S., Piccolo, R., Vranckx, P., Branca, M., Serruys, P. W. J. C., Benit, E., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa106 · Cited by 64
Self-citationFranchi, F., Rollini, F., Rios, J. R. R., Rivas, A., Agarwal, M., Kureti, M., Nagaraju, D., Wali, M., Shaikh, Z., Briceno, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.033983 · Cited by 62
Antithrombotic therapy in diabetes: which, when, and for how long?
Ajjan, R., Kietsiriroje, N., Badimón, L., Vilahur, G., Gorog, D. A., Angiolillo, D. J., Russell, D., Rocca, B., & Storey, R. F. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab128 · Cited by 74
Self-citationAcute, periprocedural and longterm antithrombotic therapy in older adults
Andreotti, F., Geisler, T., Collet, J., Gigante, B., Gorog, D. A., Halvorsen, S., Lip, G. Y. H., Morais, J., Navarese, E. P., Patrono, C., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac515 · Cited by 70
Self-citationMaking Sense of Composite Endpoints in Clinical Research
Baracaldo-Santamaría, D., Feliciano-Alfonso, J. E., Grueso, R. R., Rojas-Rodríguez, L. C., Domínguez-Domínguez, C. A., & Calderón‐Ospina, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12134371 · Cited by 74
“This study was a multicenter, randomized, double-blind clinical trial [11] comparing ticagrelor and clopidogrel for the prevention of cardiovascular events in patients with acute coronary syndrome (ACS).”
MethodHeart Disease Mortality in the United States, 1970 to 2022
King, S., Yuthok, T. Y. W., Bacong, A. M., Khandelwal, A., Kazi, D. S., Mussolino, M. E., Wong, S. S., Martin, S. S., Lewis, E. F., Rodríguez, F., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038644 · Cited by 77
Teng, R. (2012) · Clinical Pharmacokinetics · doi:10.2165/11630960-000000000-00000 · Cited by 62
Ticagrelor Improves Peripheral Arterial Function in Patients with a Previous Acute Coronary Syndrome
Törngren, K., Öhman, J. N., Salmi, H., Larsson, J., & Erlinge, D. (2013) · Cardiology · doi:10.1159/000347122 · Cited by 62
Valle, J. A., Shetterly, S. M., Maddox, T. M., Ho, P. M., Bradley, S. M., Sandhu, A., Magid, D. J., & Tsai, T. T. (2016) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.115.003519 · Cited by 65
Arntz, H.-R., Bossaert, L. L., Danchin, N., & Nikolaou, N. I. (2010) · Resuscitation · doi:10.1016/j.resuscitation.2010.08.016 · Cited by 75
Faxon, D., Airaksinen, J., Schlitt, A., Marìn, F., Bhatt, D., Lip, G., & Rubboli, A. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-08-0681 · Cited by 60
Elinogrel: Pharmacological Principles, Preclinical and Early Phase Clinical Testing
Ueno, M., Rao, S. V., & Angiolillo, D. J. (2010) · Future Cardiology · doi:10.2217/fca.10.67 · Cited by 60
Braun, O. Ö., Bico, B., Chaudhry, U. A., Wagner, H., Koul, S. M., Tydén, P., Scherstén, F., Jovinge, S. V., Svensson, P. J., Smith, J. G., et al. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.10.016 · Cited by 61
Precision Cardiovascular Medicine: State of Genetic Testing
Giudicessi, J. R., Kullo, I. J., & Ackerman, M. J. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.01.015 · Cited by 65
Ogawa, A., Toyoda, Ḱ., Kitagawa, K., Kitazono, T., Nagao, T., Yamagami, H., Uchiyama, S., Tanahashi, N., Matsumoto, M., Minematsu, K., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30449-6 · Cited by 61
Adair, B. D., Alonso, J. L., Agthoven, J. F. V., Hayes, V., Ahn, H.-S., Yu, I., Lin, S., Xiong, J.-P., Poncz, M., & Arnaout, M. A. (2020) · Nature Communications · doi:10.1038/s41467-019-13928-2 · Cited by 60
Joshi, A., Schmidt, L. E., Burnap, S. A., Lu, R., Chan, M. V., Armstrong, P. C. J., Baig, F., Gutmann, C., Willeit, P., Santer, P., et al. (2021) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.121.317113 · Cited by 60
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery
Bhatt, D. L., Pollack, C. V., Mazer, C. D., Angiolillo, D. J., Steg, P. G., James, S. K., Weitz, J. I., Ramnath, R., Arnold, S. E., Mays, M. C., et al. (2021) · NEJM Evidence · doi:10.1056/evidoa2100047 · Cited by 67
Self-citationMusumeci, G., Capodanno, D., Lettieri, C., Limbruno, U., Tarantini, G., Russo, N., Calabria, P., Romano, M., Inashvili, A., Sirbu, V., et al. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-05-0436 · Cited by 60
Ariotti, S., Ortega‐Paz, L., van Leeuwen, M., Brugaletta, S., Leonardi, S., Akkerhuis, K. M., Rimoldi, S. F., Janssens, G. N., Gianni, U., van den Berge, J. C., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2018.04.022 · Cited by 60
“During the clinical development program of ticagrelor, dyspnea and ventricular pauses were observed in some patients and confirmed at a pivotal approval study (13).”
BackgroundClopidogrel and Proton Pump Inhibitors
Tantry, U. S., Kereiakes, D. J., & Gurbel, P. A. (2011) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2010.12.009 · Cited by 60
Calabrò, P., Gragnano, F., Maio, M. D., Patti, G., Antonucci, E., Cirillo, P. L., Gresele, P., Palareti, G., Pengo, V., Pignatelli, P., et al. (2018) · Angiology · doi:10.1177/0003319718760917 · Cited by 61
Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome
Opstal, T. S. J., Fiolet, A. T. L., van Broekhoven, A., Mosterd, A., Eikelboom, J. W., Nidorf, S. M., Thompson, P. L., Duyvendak, M., van Eck, J. W. M., van Beek, E. A., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.06.037 · Cited by 66
Gandhi, S., Garratt, K. N., Li, S., Wang, T. Y., Bhatt, D. L., Davis, L. L., Zeitouni, M., & Kontos, M. C. (2022) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.121.008112 · Cited by 63
Brieger, D. B., Cullen, L., Briffa, T. G., Zaman, S. J., Scott, I. A., Papendick, C., Bardsley, K., Baumann, A. A. W., Bennett, A., Clark, R. A., et al. (2025) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.02.102 · Cited by 74
Karve, A. M., Seth, M., Sharma, M., Lalonde, T. A., Dixon, S. R., Wohns, D., & Gurm, H. S. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.02.049 · Cited by 59
Metadata
- Authors
- Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., Mahaffey, K. W., Scirica, B. M., Skene, A., Steg, P. G., Storey, R. F., & Harrington, R. A.
- Affiliations
- Uppsala University (SE)
- Duke Clinical Research Institute (US)
- Grochowski Hospital (PL)
- Brigham and Women's Hospital (US)
- AstraZeneca (Sweden) (SE)
- Aarhus University Hospital (DK)
- University Hospital Heidelberg (DE)
- University of Sheffield (GB)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-09-10
- Volume
- 361
- Issue
- 11
- Pages
- 1045-1057
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2140501627
- Cited by
- 7,117
- References
- 35
- Citations by year
- 2026: 214 · 2025: 277 · 2024: 267 · 2023: 359 · 2022: 411 · 2021: 454 · 2020: 500 · 2019: 472 · 2018: 473 · 2017: 480 · 2016: 494 · 2015: 522 · 2014: 467 · 2013: 520 · 2012: 464
- FWCI
- 253.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Debrecen Electronic Archive (University of Debrecen) (submittedVersion, other-oa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- ticagrelor, clopidogrel, acute coronary syndrome, ST-elevation myocardial infarction, P2Y12 inhibitors, platelet aggregation inhibition, major adverse cardiovascular events, major bleeding, intracranial hemorrhage, myocardial infarction, vascular death, stroke, dual antiplatelet therapy, antiplatelet therapy, drug safety and efficacy comparison
- MeSH terms
- Clopidogrel, Ticagrelor, Adenosine, Aged, Double-Blind Method, Dyspnea, Electrocardiography, Female, Hemorrhage, Humans, Male, Myocardial Infarction, Platelet Aggregation Inhibitors, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.